App-Quantinova.ai

Efficacy of daratumumab combination regimen in patients with multiple myeloma: a combined analysis of six phase III randomised controlled trials

T. W. Htut - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Dexamethasone

A narrative inquiry into patients’ experience of receiving blood transfusions in a day unit setting whilst in a palliative stage of a haematological malignancy

L. Lloyd - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Anxiety

N/A

Improving haematology clinics: Chesterfield Royal Hospital experience

R. Faulkner - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Optimising services by offering care closer to home: the introduction of telephone consultations for patients on treatment for liver Graft vs Host Disease

L. Ricketts - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Graft-versus-host disease

N/A

Rolling out adult and paediatric, patient centred Emicizumab education, counselling and administration training: Experience from a Haemophilia commissioned network covering a large catchment area

H. Cordial - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Hemophilia

N/A

Implementing a venetoclax nursing care plan for a safe administration in a haematology setting

R. Bowen - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Chronic Lymphocytic Leukemia

Venetoclax

Becoming a nurse principal investigator

E. Williams - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Albert

An eight week pilot of a weekly haematology day unit information evening event

H. Cosh - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Nurse Led DVT service over the last 17 years: IVDU (intravenous drug users) comparison to general population

Z. Lester - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Deep vein thrombosis

N/A

Capillary blood sampling for anti‐Xa monitoring in paediatric patients‐ a practice changing quality improvement project at Birmingham Children's Hospital

C. Horgan - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Heparin

Significant levels of endogenous formaldehyde in humans – a potential driver of Fanconi anaemia?

L. Glover - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Acute Leukemia

Cisplatin

Intensive care admissions for children with acute lymphoblastic leukaemia: a 13 years single centre experience

M. Rompola - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Sepsis

N/A

Transcranial doppler screening programme in children and adolescents with sickle cell disease: experience in a District General Hospital in the UK

A. Qureshi - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Sickle cell anemia

N/A

Complex paediatric apheresis support for advanced therapies

N. O'Brien - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Neuroblastoma

N/A

Does a specific factor VII mutation predict a risk of neonatal intracranial haemorrhage?

L. George - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Factor VII deficiency

N/A

Heath‐related quality of life following initial diagnosis of childhood immune thrombocytopenia

P. Greenwood - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Immune thrombocytopenia

IVIG

Effects of luspatercept on iron overload and impact on responders to luspatercept: results from the BELIEVE Trial

J. Porter - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Hemochromatosis

luspatercept

C3 inhibition with pegcetacoplan in the treatment of subjects with paroxysmal nocturnal hemoglobinuria

C. de Castro - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

One‐year efficacy of ravulizumab (ALXN1210) in adult patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibitors

H. Schrezenmeier - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

One‐year efficacy and safety from a phase 3 trial of ravulizumab in adult patients with paroxysmal nocturnal hemoglobinuria receiving prior eculizumab treatment

A. Kulasekararaj - British Society for Hematology (BSH) , 2020

Therapeutic Area

Disease

Drug/Treatment

Blood/haematological Diseases

Paroxysmal nocturnal hemoglobinuria

Eculizumab

Filters

45280 Abstracts